论文部分内容阅读
目的观察辛伐他汀治疗原发性高脂血症的疗效及安全性。方法选择原发性高脂血症患者58例,口服辛伐他汀(20mg)治疗8周,比较治疗前、治疗后4周、8周血脂及其它相关指标。结果口服辛伐他汀8周治疗高脂血症,总胆固醇(TC)下降25.44%,P<0.001;甘油三酯(TG)下降13.78%,P<0.05;低密度脂蛋白胆固醇(LDL-C)下降31.75%,P<0.001;高密度脂蛋白胆固醇(HDL-C)升高5.44%,P<0.05。辛伐他汀治疗8周血脂改善个体疗效 TC、TG、LDL-C、HDL-C 分别为81.03%、65.71%、86.21%和54.55%。不良反应发生率为5.17%,主要为消化系统症状,不影响治疗。未见肝脏酶和磷酸肌酸激酶(CK)增高。结论辛伐他汀(20mg)可明显降低 TC、TG 及 LDL-C,升高 HDL-C,安全性良好,但也应定期监测肝脏酶和 CK,积极合理调脂治疗。
Objective To observe the efficacy and safety of simvastatin in the treatment of primary hyperlipidemia. Methods 58 patients with primary hyperlipidemia were treated with 20 mg of simvastatin orally for 8 weeks. The levels of serum lipids and other relevant indexes were compared before treatment, 4 weeks and 8 weeks after treatment. Results Total cholesterol (TC) decreased by 25.44% (P <0.001), triglyceride (TG) decreased by 13.78%, P <0.05; low density lipoprotein cholesterol (LDL-C) Decreased by 31.75%, P <0.001; high density lipoprotein cholesterol (HDL-C) increased by 5.44%, P <0.05. The TC, TG, LDL-C and HDL-C of simvastatin treatment for 8 weeks were 81.03%, 65.71%, 86.21% and 54.55% respectively. The incidence of adverse reactions was 5.17%, mainly for digestive symptoms, does not affect the treatment. No liver enzymes and creatine phosphokinase (CK) increased. Conclusion Simvastatin (20mg) can significantly reduce the TC, TG and LDL-C, increase HDL-C, good safety, but also regular monitoring of liver enzymes and CK, a positive and rational lipid-lowering treatment.